the Effect of HCG Treatment as a Cardiovascular Disease Morbidity Factor in Sjogren Syndrome Patients (HAS)
Retrospective Study That Evaluate the Effect of HCG Treatment as a Cardiovascular Disease Morbidity Factor in Patients With Primary Sjogren Syndrome
sjogren syndrome is an autoimmune disease that mainly affects the Salivary glands and Lacrimal gland In addition to the effects of this disease is characterized by overall systemic Muskals injury, pulmonary disease, peripheral neuropathy and vasculitis. In addition recent studies have shown that patients are at increased risk of the disease up to 2 cardiac events and stroke events Hydroxychloroquine is an RHEUMATIC DISEASE PROCESS SUPPRESSANTS-ANTIMALARIALS used to treat anti-inflammatory rheumatic diseases in many first-line treatment is sjogren syndrome.
A recent study of the treatment in Hydroxychloroquine effect on lipid profile sjogren syndrome patients showed a reduction in total cholesterol levels and increase in HDL. Further studies of the impact made Hydroxychloroquine systemic lupus patients erythematosus (SLE) showed in Atherosclerosis and morbidity and mortality reduction in cardiovascular. Studies of patients with rheumatoid arthritis (RA) demonstrated reduced risk of developing diabetes and improved lipid profile Research Goals valuate The effect of HCQ treatment in cardiovascular patients with primary sjogren syndrome
調査の概要
詳細な説明
Research Goals Valuate The effect of HCQ treatment in cardiovascular patients with primary sjogren syndrome Research Methods The study will included patients that diagnosed with sjogren syndrome and was treated in Meir Medical center during the years 2003-2014 During the study will collect information on confounding factors , Risk factors include cardiovascular acceptable such as diabetes, dyslipidemia, high blood pressure and the like, central nervous system involvement and steroid use
Study outcome will be one of the follow:
- Thrombosis of peripheral veins
- Arterial cardiovascular events
- Cardiac events (myocardial infarction
- Stroke (stroke and TIA)
4. Venous thrombosis events 5. Pulmonary embolism In the study will be 500 patients
Inclusion criteria:
- 18 years old
- Both sexes
- Patients that diagnosis in sjogren in treated in Meir Medical center in the years 2003-2014 And treated in Hydroxychloroquine at least a month.
Exclusion criteria:
- Minors and special populations
- Patients that treated in Hydroxychloroquine at less than a month.
- Patient that participate in clinical trial and treat with investigational product
研究の種類
入学 (予想される)
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
説明
Inclusion Criteria:
- 18 years old
- Both sexes
- Patients that diagnosis in sjogren in treated in Meir Medical center in the years 2003-2014 And treated in Hydroxychloroquine at least a month.
Exclusion Criteria:
- Minors and special populations
- Patients that treated in Hydroxychloroquine at less than a month.
- Patient that participate in clinical trial and treat with investigational product
研究計画
研究はどのように設計されていますか？
デザインの詳細
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
時間枠 |
|---|---|
|
Arterial cardiovascular events
時間枠：15 years since the first dose of hydroxychloroquine
|
15 years since the first dose of hydroxychloroquine
|
二次結果の測定
結果測定 |
時間枠 |
|---|---|
|
Cardiac events (myocardial infarction
時間枠：15 years since the first dose of hydroxychloroquine
|
15 years since the first dose of hydroxychloroquine
|
|
Thrombosis of peripheral veins
時間枠：15 years since the first dose of hydroxychloroquine
|
15 years since the first dose of hydroxychloroquine
|
|
Stroke (stroke and TIA)
時間枠：15 years since the first dose of hydroxychloroquine
|
15 years since the first dose of hydroxychloroquine
|
|
Venous thrombosis events
時間枠：15 years since the first dose of hydroxychloroquine
|
15 years since the first dose of hydroxychloroquine
|
|
Pulmonary embolism
時間枠：15 years since the first dose of hydroxychloroquine
|
15 years since the first dose of hydroxychloroquine
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始
一次修了 (予想される)
研究の完了 (予想される)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (見積もり)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。